Pregled bibliografske jedinice broj: 1239049
Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction
Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction // Journal of Clinical Medicine, 12 (2023), 1; 42, 15 doi:10.3390/jcm12010042 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1239049 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in
Patients with Heart Failure and Reduced Ejection Fraction
Autori
Mustapić, Ivona ; Baković, Darija ; Sušilović Grabovac, Zora ; Borovac, Josip Anđelo
Izvornik
Journal of Clinical Medicine (2077-0383) 12
(2023), 1;
42, 15
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
SGLT2 inhibitors ; right ventricular function ; two-dimensional speckle tracking echocardiography ; three-dimensional echocardiography ; remodeling ; heart failure with reduced ejection fraction ; HFrEF ; RV
Sažetak
Background: The impact of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in addition to optimal medical therapy (OMT) on the right ventricular (RV) systolic function using advanced echocardiographic analysis among outpatients with heart failure and a reduced ejection fraction (HFrEF) has thus far been poorly investigated. Methods: This was a single-center, prospective, single- blinded study in which an echocardiographic expert was blinded to the allocation of the treatment. A total of 36 outpatients with HFrEF were randomized to either OMT or OMT+SGLT2i. Both groups underwent an echocardiographic examination of the RV systolic function at the baseline and at the 3-month follow-up (3mFU). Results: The patients in both groups did not significantly differ with respect to the relevant baseline comorbidities, therapy, and clinical characteristics. The patients receiving OMT+SGLT2i showed a significant improvement from the baseline to the 3mFU in all the measured RV echocardiographic parameters, while for the OMT group, a significant improvement after the 3mFU was observed for TAPSE and s’. The mean percent change from the baseline to the 3mFU was significant when comparing OMT+SGLT2i to the OMT group concerning RV FWS (+91% vs. +28%, p = 0.039), TR maxPG (−27% vs. +19%, p = 0.005), and TR Vmax (−17% vs. +13%, p = 0.008), respectively. Conclusions: Adding SGLT2i to OMT in patients with HFrEF resulted in a greater improvement in the RV systolic function from the baseline to the 3mFU compared to the OMT alone.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split,
Medicinski fakultet, Split,
Sveučilište u Splitu Sveučilišni odjel zdravstvenih studija
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI